glp-1 heart failure reduced ejection fraction Frontiers Glucagon-Like Peptide 1 Receptor Agonists

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

Reports describe faster wound contraction and closure rates in experimental groups compared to controls, along with a shorter timeframe to full recovery

Nutritionally variant streptococci

Amodei, L., Ruggieri, A

But its important to point out that the labor market is also showing increasing signs of weakness